Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AdV-tk |
| Synonyms | |
| Therapy Description |
ADV-tk (aglatimagene besadenovec) is an engineered adenoviral vector expressing the herpes simplex virus thymidine kinase that sensitizes tumor cells to therapy with acyclic guanosine analogues (PMID: 26843484, PMID: 30883662). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AdV-tk | Aglatimagene besadenovec|GliAtak|ProstAtak|CAN-2409|CAN2409|Virafir | ADV-tk (aglatimagene besadenovec) is an engineered adenoviral vector expressing the herpes simplex virus thymidine kinase that sensitizes tumor cells to therapy with acyclic guanosine analogues (PMID: 26843484, PMID: 30883662). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03576612 | Phase I | AdV-tk Temozolomide Valacyclovir Nivolumab | GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas (GMCI) | Completed | USA | 0 |
| NCT04495153 | Phase II | AdV-tk | GMCI Plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC | Active, not recruiting | USA | 0 |